Zoetis. has filed a patent related to canine antibody variants, focusing on mutations in the constant region to enhance characteristics like half-life. The claim mentions the cancellation of claims 1-82. GlobalData’s report on Zoetis gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Zoetis Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Zoetis, Personalized cancer vaccines was a key innovation area identified from patents. Zoetis's grant share as of January 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.

Improving canine antibody half-life and characteristics

Source: United States Patent and Trademark Office (USPTO). Credit: Zoetis Inc

A recent patent application (Publication Number: US20240010716A1) discloses a modified IgG molecule designed for increased efficacy in canines. The modified IgG includes a canine IgG constant domain with specific amino acid substitutions, notably at position 434 where asparagine is replaced with histidine (N434H). This modified IgG is specifically tailored as an anti-TGFß molecule, with defined variable heavy and light chain sequences. The patent claims that this modified IgG exhibits higher affinity for FcRn and a longer half-life compared to wild-type canine IgG constant domain IgG molecules.

Furthermore, the patent application includes claims for a pharmaceutical composition containing the modified IgG, a kit with the modified IgG and instructions for use, a fusion molecule incorporating the modified IgG, and a method for increasing the serum half-life of canine IgG in dogs through the administration of the modified IgG. The method involves administering the modified IgG with specific amino acid substitutions, along with the anti-TGFß molecule components. The patent emphasizes the importance of the specific amino acid substitutions in enhancing the serum half-life of the canine IgG molecule, potentially leading to improved therapeutic outcomes in canines.

To know more about GlobalData’s detailed insights on Zoetis, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies